Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Key Inclusion Criteria * Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome) * Age 18 years or older * Relapsed or refractory to at least 1 prior systemic therapy * Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2 * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Life expectancy ≥ 6 months * Adequate respiratory function * Adequate bone marrow function * Adequate renal and hepatic function Key Exclusion Criteria * Known central nervous system (CNS) involvement by lymphoma * Previously received immune checkpoint therapy * Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer * Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions * Severe or debilitating pulmonary disease * Clinically significant cardiovascular disease * Active fungal, bacterial, and/or viral infection requiring systemic therapy * Known infection with HIV or active viral hepatitis B or C infection * Major surgery within 4 weeks of the first dose of study drug * Pregnant or lactating women…